Biogen Inc. Files Proxy Statement Addendum

TL;DR

Biogen dropped more proxy docs, no fee needed.

AI Summary

Biogen Inc. filed a Definitive Additional Materials (DEFA14A) document on June 2, 2025. This filing pertains to the company's proxy statement, indicating it's providing supplementary information to shareholders. The filing does not involve a fee, as indicated by the 'No fee required' checkbox.

Why It Matters

This filing provides additional information to Biogen's shareholders regarding matters to be voted on at their upcoming meeting, ensuring transparency in corporate governance.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement addendum and does not contain new financial information or significant corporate actions that would immediately impact stock price.

Key Players & Entities

• BIOGEN INC. (company) — Registrant
• 225 BINNEY STREET (location) — Business Address
• CAMBRIDGE (location) — Business Address City
• MA (location) — Business Address State
• 02142 (location) — Business Address Zip
• 7814642000 (phone_number) — Business Phone

FAQ

From the Filing

0001193125-25-132885.txt : 20250602 0001193125-25-132885.hdr.sgml : 20250602 20250602092036 ACCESSION NUMBER: 0001193125-25-132885 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20250602 DATE AS OF CHANGE: 20250602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 251013304 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 DEFA14A 1 d944881ddefa14a.htm DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 BIOGEN INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. Dear Fellow Stockholders, Ahead of the annual meeting of Biogen Inc. (“Biogen” or the “Company”) on June 17, 2025, the Board of Directors (the “Board”) and Compensation and Management Development Committee (the “CMDC”) want to express our appreciation for our stockholders’ consistent support of the Company over many years. The Board has provided oversight of our long-term strategy to create sustainable stockholder value, while the CMDC has continuously improved our compensation program to align with Company performance and stockholder value. Our executive compensation program is designed to attract and retain the talented and experienced management team required to achieve our goals. Biogen’s Ongoing Transformation Focused on Delivering Long-Term Stockholder Value We embarked on a multi-year transformational journey in 2023 to achieve our goal of long-term sustainable growth under the leadership of our Chief Executive Officer (“CEO”), Chris Viehbacher, who joined us in November 2022. Biogen’s vision and actions include: • Instituting a portfolio transition that shifts focus from legacy products to growth areas. • Reducing and redeploying the company cost base. • Focusing the Research and Development portfolio on value creating programs; and • Seeking and executing on external growth opportunities. These actions create a foundation for future growth and we look forward to key pipeline readouts that begin in 2026. We believe our executive compensation philosophy properly reflects this context, aligning total compensation with long term value creation and Total Shareholder Return (“TSR”), while also recognizing the achievement of near-term milestones with the Short-Term Incentive (“STI”) program design. In 2024, the Company achieved key m